论文部分内容阅读
目的 评价那格列奈与甘精胰岛素联合治疗2型糖尿病(T2DM)患者的疗效及耐受性.方法 57例60岁以上T2DM患者住院应用那格列奈与甘精胰岛素联合治疗,评估其空腹血糖、餐后血糖及糖化血红蛋及血糖波动情况.结果 那格列奈与甘精胰岛素联合治疗后早餐前、午餐后2 h、晚餐后2 h及睡前平均血糖较治疗前明显下降(P<0.05);早餐后2 h及午餐前血糖较治疗前降低明显(P0.05).结论 那格列奈与甘精胰岛素合用可安全有效地用于60岁以上T2DM患者的治疗.“,”Objective To evaluate the effect and tolerance of co-administration of nateglinide and insulin glargine in type 2 diabetes (T2DM). Methods The fasting blood glucose (FBG), postprandial blood glucose(BG), glycosylated hemoglobin(HbA) and the undulation of blood glucose with co-administration of nateglinide and insulin glargine were evaluated in 57 T2DM greater than 60 yrars old. Results Compared to beforetreatment, BG was significantly decreased after co-administration of nateglinide and insulin glargine before breakfast, at 2 hours after lunch and supper and before retiring (P<0. 05), which was more at 2 hours after breakfast and before lunch (P 0. 05). Conclusion Nateglinide combined with insulin glargine can be used effectively and safely to treat T2DM patients aged greater than 60 yrars old.